Market ExpansionThe market for treatments is projected to grow to $2.8 billion, offering significant growth potential for Sofdra.
Revenue GrowthSofdra net revenue increased from $0.7 million to $4.3 million, highlighting strong financial performance.
Strategic PositioningSofdra is positioned to fill the PAH treatment gap, supported by previous approval in Japan and its differentiated mechanism.